CompletedPhase 2NCT03624010
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Studying Dextrocardia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tenax Therapeutics, Inc.
- Principal Investigator
- Stuart Rich, MDTenax Therapeutics, Inc.
- Intervention
- Levosimendan 2.5 mg/ml Injectable Solution(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2024
Study locations (9)
- Stanford Healthcare, Stanford, California, United States
- Northwestern Memorial Hospital, Chicago, Illinois, United States
- University of Minnesota Medical Center, Minneapolis, Minnesota, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- UW Health University Hospital, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03624010 on ClinicalTrials.gov